Audit Review Table Presbyterian Health Plan, Inc. (Org ID: 579, SubID: 4104, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2011 The Plan lock has been applied to this submission. Report Benefit Rotated Measure/Data Element Reportable Comment Rate Measure Offered Measure **Effectiveness of Care: Prevention and Screening** Adult BMI Assessment (aba) Υ R Reportable 59.37% Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents Υ (wcc) BMI Percentile 26.76% R Reportable Counseling for Nutrition 45.99% R Reportable Counseling for Physical Activity R Reportable 34.06% Υ **Childhood Immunization Status (cis)** DTaP 75.67% R Reportable IPV R 90.02% Reportable MMR 87.35% R Reportable HiB 90.02% R Reportable Hepatitis B 85.40% R Reportable **VZV** 87.35% R Reportable R Pneumococcal Conjugate 78.59% Reportable Hepatitis A 27.49% R Reportable R Rotavirus 69.34% Reportable R Influenza 52.31% Reportable Combination #2 70.07% R Reportable R Combination #3 67.64% Reportable R Combination #4 23.84% Reportable R Combination #5 56.45% Reportable 42.82% R Combination #6 Reportable R Combination #7 20.92% Reportable R 15.33% Reportable Combination #8 R Combination #9 35.77% Reportable Combination #10 13.14% R Reportable Immunizations for Adolescents (ima) Υ Meningococcal 59.37% R Reportable

Tdap/Td

74.21%

R

Reportable

Combination #1				57.18%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hpv)	Υ			22.38%	R	Reportable
Lead Screening in Children (Isc)	Υ			26.28%	R	Reportable
Breast Cancer Screening (bcs)	Υ			45.66%	R	Reportable
Cervical Cancer Screening (ccs)	Y		N	60.58%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
16-20 Years				43.31%	R	Reportable
21-24 Years				59.07%	R	Reportable
Total				47.84%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Υ	Y		66.84%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Υ	Y		84.70%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Υ	Y		18.29%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Υ			22.11%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Υ	Y				
Systemic Corticosteroid				75.64%	R	Reportable
Bronchodilator				87.18%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Υ	Y				
5-11 Years				89.99%	R	Reportable
12-18 Years				81.45%	R	Reportable
19-50 Years				63.90%	R	Reportable
51-64 Years				59.02%	R	Reportable
Total				82.85%	R	Reportable
Medication Management for People With Asthma (mma)	Υ	Y				
5-11 Years - Medication Compliance 50%				48.57%	R	Reportable
5-11 Years - Medication Compliance 75%				24.90%	R	Reportable
12-18 Years - Medication Compliance 50%				50.48%	R	Reportable
12-18 Years - Medication Compliance 75%				22.45%	R	Reportable
19-50 Years - Medication Compliance 50%				58.19%	R	Reportable

19-50 Years - Medication Compliance 75%				40.68%	R	Reportable
51-64 Years - Medication Compliance 50%				69.44%	R	Reportable
51-64 Years - Medication Compliance 75%				38.89%	R	Reportable
Total - Medication Compliance 50%				50.58%	R	Reportable
Total - Medication Compliance 75%				25.86%	R	Reportable
Effectiveness of Care: Cardiovascular						
Cholesterol Management for Patients With	Υ					
Cardiovascular Conditions (cmc)	T .					
LDL-C Screening Performed				85.71%	R	Reportable
LDL-C Control (<100 mg/dL)				43.48%	R	Reportable
Controlling High Blood Pressure (cbp)	Υ		N	62.77%	R	Reportable
Persistence of Beta-Blocker Treatment After a	Υ	Y		NA	R	Denominator fewer than 30
Heart Attack (pbh)	<u> </u>	ī		INA	K	Denominator lewer triair 50
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y					
Hemoglobin A1c (HbA1c) Testing				84.67%	R	Reportable
HbA1c Poor Control (>9.0%)				41.06%	R	Reportable
HbA1c Control (<8.0%)				49.27%	R	Reportable
HbA1c Control (<7.0%)				37.56%	R	Reportable
Eye Exam (Retinal) Performed				50.55%	R	Reportable
LDL-C Screening Performed				72.45%	R	Reportable
LDL-C Control (<100 mg/dL)				34.49%	R	Reportable
Medical Attention for Nephropathy				72.81%	R	Reportable
Blood Pressure Control (<140/80 mm Hg)				42.88%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)				63.50%	R	Reportable
Effectiveness of Care: Musculoskeletal						
Disease Modifying Anti-Rheumatic Drug Therapy in	Y	Y		73.97%	R	Reportable
Rheumatoid Arthritis (art)	<u> </u>	ī		73.97%	K	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Υ			79.65%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	N	N				
Effective Acute Phase Treatment				NR	NR	Measure Unselected
Effective Continuation Phase Treatment				NR	NR	Measure Unselected
Follow-Up Care for Children Prescribed ADHD Medication (add)	Υ	Y				

Initiation Phase			37.57%	R	Reportable
Continuation and Maintenance (C&M) Phase			45.26%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	N	N			
30-Day Follow-Up			NR	NR	Measure Unselected
7-Day Follow-Up			NR	NR	Measure Unselected
Effectiveness of Care: Medication Management					
Annual Monitoring for Patients on Persistent Medications (mpm)	Υ	Y			
ACE Inhibitors or ARBs			84.48%	R	Reportable
Digoxin			NA	R	Denominator fewer than 30
Diuretics			86.81%	R	Reportable
Anticonvulsants			69.70%	R	Reportable
Total			83.05%	R	Reportable
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (aap)	Υ				
20-44 Years			85.77%	R	Reportable
45-64 Years			87.41%	R	Reportable
65+ Years			83.53%	R	Reportable
Total			86.18%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y				
12-24 Months			98.28%	R	Reportable
25 Months - 6 Years			88.81%	R	Reportable
7-11 Years			91.23%	R	Reportable
12-19 Years			90.33%	R	Reportable
Annual Dental Visit (adv)	Υ	Y			
2-3 Years			54.24%	R	Reportable
4-6 Years			76.40%	R	Reportable
7-10 Years			80.59%	R	Reportable
11-14 Years			75.49%	R	Reportable
15-18 Years			63.93%	R	Reportable
19-21 Years			45.57%	R	Reportable
Total			71.51%	R	Reportable

Initiation and Engagement of AOD Dependence Treatment (iet)	N	N				
Initiation of AOD Treatment: 13-17 Years				NR	NR	Measure Unselected
Engagement of AOD Treatment: 13-17 Years				NR	NR	Measure Unselected
Initiation of AOD Treatment: 18+ Years				NR	NR	Measure Unselected
Engagement of AOD Treatment: 18+ Years				NR	NR	Measure Unselected
Initiation of AOD Treatment: Total				NR	NR	Measure Unselected
Engagement of AOD Treatment: Total				NR	NR	Measure Unselected
Prenatal and Postpartum Care (ppc)	Υ		N			
Timeliness of Prenatal Care				81.02%	R	Reportable
Postpartum Care				56.45%	R	Reportable
Call Answer Timeliness (cat)	Υ			86.13%	R	Reportable
Call Abandonment (cab)	Υ			1.93%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Υ		N			
<21 Percent				10.71%	R	Reportable
21-40 Percent				3.65%	R	Reportable
41-60 Percent				8.03%	R	Reportable
61-80 Percent				16.06%	R	Reportable
81+ Percent				61.56%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Υ					
0 Visits				0.73%	R	Reportable
1 Visit				0.00%	R	Reportable
2 Visits				2.68%	R	Reportable
3 Visits				3.65%	R	Reportable
4 Visits				6.57%	R	Reportable
5 Visits				21.90%	R	Reportable
6+ Visits				64.48%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Υ			61.07%	R	Reportable
Adolescent Well-Care Visits (awc)	Υ			39.66%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Υ				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	Υ				R	Reportable

Ambulatory Care: Disabled (ambc)	Υ		R	Reportable
Ambulatory Care: Other (ambd)	Υ		R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Total (ipua)	Υ		R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Dual Eligibles (ipub)	Υ		R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Disabled (ipuc)	Y		R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Other (ipud)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Total (iada)	N	N	NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N	NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N	NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N	NR	Measure Unselected
Mental Health Utilization: Total (mpta)	N	N	NR	Measure Unselected
Mental Health Utilization: Dual Eligibles (mptb)	N	N	NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N	NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N	NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Υ	Υ	R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Υ	Υ	R	Reportable
Antibiotic Utilization: Disabled (abxc)	Υ	Υ	R	Reportable
Antibiotic Utilization: Other (abxd)	Υ	Υ	R	Reportable
Relative Resource Use				
Relative Resource Use for People With Diabetes (rdi)	Υ		R	Reportable
Relative Resource Use for People With Asthma (ras)	Υ	Y	R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Υ		R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Υ		R	Reportable

Relative Resource Use for People With COPD (rco)	Υ		R	Reportable
Health Plan Descriptive Information				
Board Certification (bcr)	Υ		R	Reportable
Total Membership (tlm)	Υ		R	Reportable
Enrollment by Product Line: Total (enpa)	Υ		R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	Υ		R	Reportable
Enrollment by Product Line: Disabled (enpc)	Υ		R	Reportable
Enrollment by Product Line: Other (enpd)	Υ		R	Reportable
Enrollment by State (ebs)	Υ		R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Υ		R	Reportable
Language Diversity of Membership (Idm)	Υ		R	Reportable
Weeks of Pregnancy at Time of Enrollment in MCO (wop)	Υ	N	R	Reportable